vaccine adjuvant is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
=== Centimorgan: Genetic linkage === In genetics, a centimorgan (abbreviated cM) or map unit (m.u.) is a unit for measuring genetic linkage. It is defined as the distance between chromosome positions (also termed loci or markers) for which the expected average number of intervening chromosomal crossovers in a single generation is 0.01. It is often used to infer distance along a chromosome. One centimorgan corresponds to about 1 million base pairs in humans on average.
==== Jersey ==== The government of Jersey signed a confidential agreement with 3M in 2005, agreeing to not pursue legal claims for £2.6m. Jersey must assist 3M in the defense of future claims. A source told The Guardian that Jersey needed 3M's permission to proceed with blood tests to avoid 3M punitive measures. "The state got an agreement to do individual blood tests, but not screening, as that could be the first step towards a possible class action lawsuit."
In January 2026, the Moore administration reached annual pay agreements with six state employee unions, but failed to reach an agreement with AFSCME Maryland Council 3, the state's largest union of state government workers, by the December 31 deadline. Despite this, a pay increase for AFSCME-represented workers equivalent to agreements reached with several smaller unions that average 2% was included in Moore's fiscal year 2027 budget proposal.
=== Insurance Services division === UPMC Insurance Services, operating under the umbrella UPMC Health Plan brand, was founded in 1998 and includes various for-profit and non-profit health care financing initiatives. The integrated products of the UPMC Insurance Services Division include UPMC Health Plan (HMO), UPMC Health Network (PPO), Workpartners (workers' compensation and disability for employers), UPMC for Life (Medicare products), UPMC for You (HMO for Medical Assistance beneficiaries), UPMC for Kids, Community Care Behavioral Health Organization (a non-profit behavioral health PPO for Medical Assistance beneficiaries) and Community HealthChoices. These products combine to offer a full range of HMOs, PPOs, and EPOs for group health insurance, Medicare, CHIP, Medical Assistance, behavioral health, employee assistance, and workers' compensation products and services. UPMC also offers consumer-directed health plans like health savings accounts and health reimbursement arrangements. UPMC's provider networks total more than 138 hospitals and more than 16,500 physicians across Pennsylvania and has around three million members making it the largest insurer in Western Pennsylvania. It is also ranked as one of the top commercial health plans in the United States according to U.S. News & World Report.
The company then initiated a second trial (CONVENE) designed to test this outcome in 2016, but it was terminated in 2016 shortly after Takeda announced that it would sell its rights to the drug in the US to Orexigen. In 2018, Orexigen sold its assets, including Contrave, to Nalpropion Pharmaceuticals.
Sources: en.wikipedia.org
== Building a PBPK model == The model equations follow the principles of mass transport, fluid dynamics, and biochemistry in order to simulate the fate of a substance in the body. Compartments are usually defined by grouping organs or tissues with similar blood perfusion rate and lipid content (i.e. organs for which chemicals' concentration vs. time profiles will be similar). Ports of entry (lung, skin, intestinal tract...), ports of exit (kidney, liver...) and target organs for therapeutic effect or toxicity are often left separate. Bone can be excluded from the model if the substance of interest does not distribute to it. Connections between compartment follow physiology (e.g., blood flow in exit of the gut goes to liver, etc.)
=== December === 4 December – Recent studies reveal that the heart contains a small control center — an independent neural network that regulates its rhythm. Gaining deeper insight into this intricate and varied system, which proves to be far more sophisticated than earlier believed, may pave the way for innovative therapies for cardiovascular conditions.
Examples: [Co(EDTA)]−, [Co(NH3)6]3+, TiCl4(THF)2. Coordination compounds show a rich diversity of structures, varying from tetrahedral for titanium (e.g., TiCl4) to square planar for some nickel complexes to octahedral for coordination complexes of cobalt. A range of transition metals can be found in biologically important compounds, such as iron in hemoglobin.
7 June Rishi Sunak is criticised for leaving the D-day commemorations early to return to the UK to work on the election campaign. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Data produced by Zoopla indicates that rents for new properties rose by 6.6% in the year to April 2024, but that this was the slowest rise in two and a half years. 9 June – Restrictions on carrying more than 100ml of liquid in hand luggage are temporarily reintroduced at some regional airports in order to "enable further improvements to be made" to new checkpoint systems. Those affected are Newcastle, Leeds Bradford, London City, Aberdeen, Southend and Teesside. 10 June – Twenty buildings across the UK are vandalised as part of a co-ordinated attack by Palestine Action, a pro-Palestine group. 11 June A High Court judge rules that convicted sex offender Gary Glitter must pay more than £500,000 to a victim he abused when she was 12 years old. A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. Former UN secretary general Ban Ki-moon is awarded the inaugural King Charles III Harmony Award during a ceremony held at St James's Palace. Two animal rights protestors vandalise a portrait of Charles III at London's Philip Mould Gallery by covering it with posters.
Sources: en.wikipedia.org
== Structure == GRF (1-29), also known as sermorelin (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2), the biologically-active portion of the 44 amino acid GHRH. Half-life "less than 10 minutes", perhaps as low as 5 minutes. Mod GRF (1-29) replacement of the 2nd, 8th, 15th, and 27th amino acids of GRF (1-29) yields modified GRF(1-29) (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2). Half-life at least 30 minutes.
citrate → cis-aconitate → isocitrate → α-ketoglutarate → succinyl-CoA → succinate → fumarate → malate → oxaloacetate → citrate In this cycle, the enzyme isocitrate dehydrogenase 3 converts isocitrate (isocitrate has 4 isomers of which only the (−)-d-threo-isomer is the naturally occurring isomer in the citric acid cycle.) to α-ketoglutarate which in the next step is converted to succinyl-CoA by the oxoglutarate dehydrogenase complex of enzymes.
=== Access to healthcare === In 2021, the French Senate's Delegation for Women's Rights reported that women's health was not considered a priority in rural areas, where medical desertification limits access to gynecological care. This can result in delayed care and inadequate cancer screening. France has faced a shortage of medical gynecologists, with some departments lacking them entirely. Medical gynecology, a discipline distinct from obstetrics and specific to France, saw a halt in specialist training from 1984 to 2003 as the country considered aligning with other European healthcare systems that do not maintain this distinction.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.